All Categories

Lilly, Incyte rheumatoid arthritis drug succeeds.

Eli Lilly and Co and Incyte Corp said a third late-stage study of their experimental rheumatoid arthritis drug met its main goal.
The drug, baricitinib, was more effective than the decades-old treatment methotrexate, after 24 weeks of treatment, in reducing signs and symptoms of the inflammatory disorder, the companies said on Tuesday.

Related Articles

Show Buttons
Hide Buttons
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker